Survival was evaluated using Cox regression and Kaplan-Meier analysis.ĬSF, serum, and plasma NfL discriminated patients with ALS from healthy controls with high sensitivity (97%, 89%, 90%, respectively) and specificity (95%, 75%, 71%, respectively). Change in ALS Functional Rating Scale-Revised score was used to assess disease progression. NfL levels in patients were measured at regular intervals for up to 3 years. Using an electrochemiluminescence immunoassay, NfL levels were measured in samples from 2 cohorts of patients with sporadic ALS and healthy controls, recruited in London (ALS/control, plasma: n = 103/42) and Oxford (ALS/control, serum: n = 64/36 paired CSF: n = 38/20). test blood and CSF neurofilament light chain (NfL) levels in relation to disease progression and survival in amyotrophic lateral sclerosis (ALS).
#CARDINAL CHAINS LEVEL 57 TRIAL#
2 From the Centre for Neuroscience & Trauma (C.-H.L., G.G., J.K., A.M.), Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London Sobell Department of Motor Neuroscience and Movement Disorders (C.-H.L., L.G.), Departments of Neuroinflammation (A.P.), Neurodegenerative Disease (P.F.), Molecular Neuroscience (K.S.), and Clinical Neuroscience (R.O.), and MRC Centre for Neuromuscular Diseases (R.O., L.G.), UCL Institute of Neurology, London MRC Integrative Epidemiology Unit (C.M.-W.), University of Bristol Nuffield Department of Clinical Neurosciences (E.G., K.T., M.R.T.), University of Oxford Department of Medical Statistics (N.P.), London School of Hygiene and Tropical Medicine, London, UK UmanDiagnostics (N.N.), Umeå, Sweden Medicine Clinical Trial Unit (M.F.), Musgrove Park Hospital, Taunton, UK National Hospital for Neurology and Neurosurgery (R.O., R.H., A.M.), London, UK Neurology (J.K.), University Hospital Basel, Switzerland North-East London and Essex MND Care and Research Centre (A.M.), London and Basildon and Thurrock University Hospitals NHS Foundation Trust (A.M.), Basildon, UK.
0 kommentar(er)
